Ronald J. Zenk

Ronald Zenk is an accomplished executive with a robust background in finance and leadership within the pharmaceutical and healthcare industries. Since December 1988, Ronald Zenk has served as the Chief Executive Officer and a member of the Board of Directors at Humanetics Corporation, a clinical-stage specialty pharmaceutical company focused on the development of BIO 300, a drug candidate aimed at preventing radiation damage and managing inflammatory diseases. Prior to this role, Ronald Zenk held the position of Vice President Finance at Surgidyne, Inc., where innovative closed-wound drainage systems were developed. Earlier in Ronald Zenk's career, experience as a Financial Management Consultant at KPMG contributed to expertise in aligning finance organizations with business strategies. Ronald Zenk holds a Master of Business Administration in Finance from the University of Minnesota - Carlson School of Management and a Bachelor's degree in Business Administration and Management from Saint John's University.